Cancer in Belarus

IARC estimates 46,420 new cancer cases and 22,838 cancer deaths in Belarus in 2024; the commonest new cancers are colorectum, breast and prostate. This page is assembled automatically from OnCo's data: 23 trials with a site there, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

46,420

all cancers

Deaths

22,838

all cancers

Incidence rate

275.3

per 100,000, age-standardised

Mortality rate

124.4

per 100,000, age-standardised

Cumulative risk

28.1%

of a cancer by age 74

Population

9,056,699

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Colorectum	6,073	31.9	Colorectal cancer
Breast	5,076	55.4	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	5,025	67.3	Prostate cancer
Trachea, bronchus and lung	4,923	28.0	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Stomach	2,789	15.2	Gastric & gastro-oesophageal junction cancer
Kidney	2,421	15.3	Renal cell carcinoma
Corpus uteri	2,198	23.6	Endometrial cancer
Bladder	1,445	7.7	Bladder & urothelial cancer
Pancreas	1,306	7.1	Pancreatic ductal adenocarcinoma
Thyroid	1,200	10.1	Thyroid cancer

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	3,873	21.3	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	3,001	14.8	Colorectal cancer
Stomach	2,133	11.4	Gastric & gastro-oesophageal junction cancer
Breast	1,394	13.4	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Pancreas	1,249	6.7	Pancreatic ductal adenocarcinoma
Prostate	1,159	15.4	Prostate cancer
Leukaemia	704	3.9	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Kidney	675	3.7	Renal cell carcinoma
Liver and intrahepatic bile ducts	555	3.0	Hepatocellular carcinoma
Ovary	551	5.4	Ovarian cancer

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 2a, national rates applied to the 2024 population.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Belarus”, in Eastern Europe (Europe), Very High HDI, upper middle income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

23 trials in OnCo · 2 recruiting overall

23 trials

Trial			Lead sponsor
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) NCT07742215	Phase 3	Recruiting	Biocad	16	2026-08-03
BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer NCT07108309	Phase 2	Recruiting	Biocad	47	2025-08-07
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC) NCT04497844	Phase 3	Active not recruiting	Janssen Research & Development, LLC	387	2026-09-28
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer NCT03473743	Phase 1/2	Active not recruiting	Janssen Research & Development, LLC	127	2026-08-28
ALINA NCT03456076	Phase 3	Active not recruiting	Hoffmann-La Roche	114	2026-07-15
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer NCT04464226	Phase 3	Active not recruiting	Bayer	335	2026-07-07
EMPOWER-Lung 1 NCT03088540	Phase 3	Completed	Regeneron Pharmaceuticals	192	2026-06-25
ROSEWOOD NCT03332017	Phase 2	Completed	BeiGene	88	2026-02-18
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer NCT03602859	Phase 3	Active not recruiting	Tesaro, Inc.	182	2025-12-31
RUBY / ENGOT-EN6 / GOG-3031 NCT03981796	Phase 3	Active not recruiting	Tesaro, Inc.	169	2025-09-03
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma NCT05751928	Phase 3	Active not recruiting	Biocad	36	2025-07-08
Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin NCT06640530	Phase 3	Active not recruiting	Biocad	44	2025-07-08
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer NCT03390686	Phase 3	Active not recruiting	Prestige Biopharma Limited	18	2025-05-31
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma NCT05732805	Phase 3	Active not recruiting	Biocad	63	2025-02-27
BROCADE3 NCT02163694	Phase 3	Completed	AbbVie	219	2025-02-19
ARAMIS NCT02200614	Phase 3	Completed	Bayer	404	2022-06-28
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) NCT03033511	Phase 3	Terminated	AbbVie	308	2021-07-29
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) NCT03061812	Phase 3	Completed	AbbVie	195	2021-02-23
FIRSTANA NCT01308567	Phase 3	Completed	Sanofi	167	2019-06-05
LUME-Lung 1 NCT00805194	Phase 3	Completed	Boehringer Ingelheim	210	2018-12-05
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) NCT00718549	Phase 3	Completed	Hoffmann-La Roche	6	2018-08-20
ROMANA 1 and ROMANA 2 NCT01387269, NCT01387282	Phase 3	Completed	Helsinn Therapeutics (U.S.), Inc	106	2017-10-27
ELM-PC 4 NCT01193244	Phase 3	Completed	Millennium Pharmaceuticals, Inc.	240	2017-05-17

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Belarus, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Belarus is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

OnCo holds no institution, company or person in Belarus.

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Belarus is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Belarus's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Belarus, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Belarus's own sources.

A deep dive for Belarus is ranked 48 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/by.json; every country: /api/v1/countries.json.